DK1326613T3 - Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering - Google Patents
Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhiberingInfo
- Publication number
- DK1326613T3 DK1326613T3 DK01972099T DK01972099T DK1326613T3 DK 1326613 T3 DK1326613 T3 DK 1326613T3 DK 01972099 T DK01972099 T DK 01972099T DK 01972099 T DK01972099 T DK 01972099T DK 1326613 T3 DK1326613 T3 DK 1326613T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazin
- pyridin
- pyrimidine
- drugs
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10050663A DE10050663A1 (de) | 2000-10-13 | 2000-10-13 | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
PCT/EP2001/011701 WO2002030428A1 (de) | 2000-10-13 | 2001-10-10 | Verwendung von substituierten imidazo[1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1326613T3 true DK1326613T3 (da) | 2004-10-11 |
DK1326613T4 DK1326613T4 (da) | 2007-09-03 |
Family
ID=7659598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01972099T DK1326613T4 (da) | 2000-10-13 | 2001-10-10 | Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040023972A1 (da) |
EP (1) | EP1326613B2 (da) |
JP (1) | JP2004510820A (da) |
AT (1) | ATE268179T1 (da) |
AU (2) | AU9189301A (da) |
CA (1) | CA2425672A1 (da) |
DE (2) | DE10050663A1 (da) |
DK (1) | DK1326613T4 (da) |
ES (1) | ES2220810T5 (da) |
HU (1) | HUP0303350A3 (da) |
MX (1) | MXPA03003200A (da) |
NZ (1) | NZ525779A (da) |
PL (1) | PL361807A1 (da) |
PT (1) | PT1326613E (da) |
SI (1) | SI1326613T2 (da) |
TR (1) | TR200401545T4 (da) |
WO (1) | WO2002030428A1 (da) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10117184A1 (de) * | 2001-04-05 | 2002-10-17 | Gruenenthal Gmbh | Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen |
DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
DE10132726A1 (de) | 2001-07-05 | 2003-02-27 | Gruenenthal Gmbh | Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel |
KR20050008691A (ko) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | 이미다조[1,2-a]피라진-8-일 아민, 그의 제조방법 및사용방법 |
DE10240735A1 (de) * | 2002-08-29 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Verwendung von Modulatoren der NO-Signalkaskade und pharmazeutische Zusammensetzung |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2005046559A2 (en) * | 2003-11-06 | 2005-05-26 | Lifescan, Inc. | Drug delivery pen with event notification means |
DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
EP1765351B9 (en) * | 2004-06-09 | 2010-03-24 | Oncalis AG | Protein kinase inhibitors |
DE102004044884A1 (de) * | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
US7923041B2 (en) * | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
AU2006247118A1 (en) * | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
US7709468B2 (en) * | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
PL2495016T3 (pl) | 2005-12-23 | 2020-06-01 | Ariad Pharmaceuticals, Inc. | Bicykliczne związki heteroarylowe |
CA2653506A1 (en) * | 2006-05-31 | 2007-12-06 | Galapagos Nv. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
DE102006028862A1 (de) * | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
WO2008016648A2 (en) * | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
RS54542B1 (en) * | 2006-08-02 | 2016-06-30 | Cytokinetics, Inc. | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INCLUDING IMIDAZOPYRIMIDINE |
US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
DE102006048728A1 (de) * | 2006-10-16 | 2008-04-17 | Merck Patent Gmbh | 3-Amino-imidazo{1,2-a]pyridinderivate |
EP1964840A1 (en) * | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
CN101652069A (zh) * | 2007-03-27 | 2010-02-17 | 艾博特公司 | 新的基于咪唑并的杂环化合物 |
US7851484B2 (en) * | 2007-03-30 | 2010-12-14 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2008134553A1 (en) * | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
DE102007040336A1 (de) * | 2007-08-27 | 2009-03-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen |
DE102007048716A1 (de) * | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
CA2704645A1 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Non-nucleoside reverse transcriptase inhibitors |
BRPI0820171B8 (pt) | 2007-11-16 | 2021-05-25 | Rigel Pharmaceuticals Inc | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos |
WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
EP2276761B1 (en) | 2008-04-23 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
CN102216298B (zh) * | 2008-09-16 | 2014-04-16 | Csir公司 | 作为hiv-1逆转录酶抑制剂的咪唑并吡啶和咪唑并嘧啶 |
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
HUE030427T2 (en) | 2008-12-08 | 2017-05-29 | Gilead Connecticut Inc | Imidazopyrazine Syk inhibitors |
IN2012DN01961A (da) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
WO2011045415A2 (en) * | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
NZ602362A (en) | 2010-03-11 | 2014-11-28 | Gilead Connecticut Inc | Imidazopyridines syk inhibitors |
US9045474B2 (en) | 2010-08-03 | 2015-06-02 | The Regents Of The University Of California | Compounds and compositions for mitigating tissue damage and lethality |
CA2849213A1 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination of riluzole and ck-2017357 for treating als |
JP6078076B2 (ja) * | 2011-11-11 | 2017-02-08 | インテリカイン, エルエルシー | キナーゼ阻害剤多形体 |
WO2014021383A1 (ja) | 2012-07-31 | 2014-02-06 | 協和発酵キリン株式会社 | 縮環複素環化合物 |
US20160030404A1 (en) * | 2013-03-15 | 2016-02-04 | The Regents Of The University Of California | Therapeutic Agents and Methods for the Treatment of DNA Repair Deficiency Disorders |
AP2016009007A0 (en) | 2013-07-30 | 2016-01-31 | Gilead Connecticut Inc | Formulation of syk inhibitors |
TW201602108A (zh) | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | 脾酪胺酸激酶(Syk)抑制劑之多晶型 |
PT3076976T (pt) | 2013-12-04 | 2020-12-07 | Kronos Bio Inc | Métodos para tratar cancros |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ES2901711T3 (es) | 2014-02-13 | 2022-03-23 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
KR20170029580A (ko) | 2014-07-14 | 2017-03-15 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하기 위한 조합물 |
WO2016033440A1 (en) * | 2014-08-29 | 2016-03-03 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
EP3692052A4 (en) | 2017-10-04 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
JP2022521413A (ja) | 2019-02-22 | 2022-04-07 | クロノス バイオ インコーポレイテッド | Syk阻害剤としての縮合ピラジンの固体形態 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507294A (en) * | 1982-03-08 | 1985-03-26 | Schering Corp. | Imidazo[1,2-a]pyrazines |
DE3269604D1 (en) * | 1981-06-26 | 1986-04-10 | Schering Corp | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
GB8415540D0 (en) * | 1984-06-18 | 1984-07-25 | Fujisawa Pharmaceutical Co | Imidazoisoquinoline compounds |
FR2638161B1 (fr) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
WO1991004027A1 (en) † | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
IE904346A1 (en) † | 1989-12-04 | 1991-06-05 | Searle & Co | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY |
CA2128199C (en) * | 1994-07-15 | 1997-02-04 | Bernard Charles Sherman | Stable solid pharmaceutical compositions containing enalapril maleate |
EP0822194A4 (en) * | 1995-04-21 | 1998-04-29 | Shinnippon Pharmaceutical Inc | ANNELLLIED IMIDAZO [1,2-a] PYRIDINE |
AU6691798A (en) † | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
EP1192346B1 (de) † | 1999-07-02 | 2004-05-12 | Siemens Aktiengesellschaft | Verfahren zum überwachen einer mit luftüberschuss betreibbaren brennkraftmaschine |
DE19948434A1 (de) * | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
DE10019714A1 (de) † | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
WO2002002557A2 (en) * | 2000-06-30 | 2002-01-10 | Neurogen Corporation | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands |
DE10246890A1 (de) * | 2002-10-08 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine |
DE10247269A1 (de) * | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
-
2000
- 2000-10-13 DE DE10050663A patent/DE10050663A1/de not_active Withdrawn
-
2001
- 2001-10-10 CA CA002425672A patent/CA2425672A1/en not_active Abandoned
- 2001-10-10 SI SI200130161T patent/SI1326613T2/sl unknown
- 2001-10-10 TR TR2004/01545T patent/TR200401545T4/xx unknown
- 2001-10-10 EP EP01972099A patent/EP1326613B2/de not_active Expired - Lifetime
- 2001-10-10 AT AT01972099T patent/ATE268179T1/de not_active IP Right Cessation
- 2001-10-10 HU HU0303350A patent/HUP0303350A3/hu unknown
- 2001-10-10 JP JP2002533869A patent/JP2004510820A/ja active Pending
- 2001-10-10 NZ NZ525779A patent/NZ525779A/en unknown
- 2001-10-10 PT PT01972099T patent/PT1326613E/pt unknown
- 2001-10-10 AU AU9189301A patent/AU9189301A/xx active Pending
- 2001-10-10 DE DE50102490T patent/DE50102490D1/de not_active Expired - Fee Related
- 2001-10-10 ES ES01972099T patent/ES2220810T5/es not_active Expired - Lifetime
- 2001-10-10 MX MXPA03003200A patent/MXPA03003200A/es active IP Right Grant
- 2001-10-10 DK DK01972099T patent/DK1326613T4/da active
- 2001-10-10 PL PL36180701A patent/PL361807A1/xx not_active Application Discontinuation
- 2001-10-10 AU AU2001291893A patent/AU2001291893B9/en not_active Ceased
- 2001-10-10 WO PCT/EP2001/011701 patent/WO2002030428A1/de active IP Right Grant
-
2003
- 2003-04-11 US US10/411,402 patent/US20040023972A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUP0303350A3 (en) | 2006-02-28 |
ES2220810T3 (es) | 2004-12-16 |
SI1326613T1 (en) | 2004-10-31 |
ATE268179T1 (de) | 2004-06-15 |
AU2001291893B8 (en) | 2006-06-15 |
AU2001291893B2 (en) | 2006-05-18 |
PL361807A1 (en) | 2004-10-04 |
EP1326613B2 (de) | 2007-04-18 |
NZ525779A (en) | 2005-01-28 |
HUP0303350A2 (hu) | 2004-01-28 |
DE50102490D1 (de) | 2004-07-08 |
CA2425672A1 (en) | 2003-04-11 |
ES2220810T5 (es) | 2007-12-01 |
DK1326613T4 (da) | 2007-09-03 |
PT1326613E (pt) | 2004-10-29 |
SI1326613T2 (sl) | 2007-08-31 |
EP1326613A1 (de) | 2003-07-16 |
MXPA03003200A (es) | 2003-07-14 |
TR200401545T4 (tr) | 2004-08-23 |
DE10050663A1 (de) | 2002-04-18 |
AU9189301A (en) | 2002-04-22 |
US20040023972A1 (en) | 2004-02-05 |
EP1326613B1 (de) | 2004-06-02 |
JP2004510820A (ja) | 2004-04-08 |
WO2002030428A1 (de) | 2002-04-18 |
AU2001291893B9 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1326613T3 (da) | Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
SE0104334D0 (sv) | Therapeutic agents | |
MY130755A (en) | Colchinol derivatives as vascular damaging agents | |
HK1057752A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
WO2005011653A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
WO2004060882A8 (en) | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | |
WO2005011655A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
BR0014596A (pt) | Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas | |
WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
WO2006035157A3 (fr) | Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques | |
HUP0302336A2 (hu) | 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására | |
MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
NO20055997L (no) | Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister | |
SE9901572D0 (sv) | New compounds | |
WO2001007029A3 (en) | Substituted guanidines and the use thereof | |
WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
WO2004089969A3 (en) | Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi | |
ECSP055804A (es) | Composición farmacéutica | |
WO2003066806A3 (en) | Therapeutic use of aziridino compounds |